Tested under dermatological control, light texture
Soothes - Hydrates - Reduces redness due to dryness - Removes flakes
A soothing gel-cream specifically developed for uncomfortable, dry skin, with redness and scaling (small plaques of skin that peel off).
• The patented* CICLOPIROXOLAMINE and PIROCTONE OLAMINE active ingredient synergy eliminates contaminant from the skin thanks to their purifying action.
• From the 1st application, redness is soothed and scales** are reduced by 50%¹
• With just 1 application a day, KELUAL DS soothing cream significantly reduces redness** and scales** in just 2 weeks. Sustainable action.
• Light gel-cream formula, specifically formulated for dry skin with redness** and scales**, hydrates while soothing the skin
With a unique patented actives association, KELUAL DS soothing cream efficiently reduces scales, redness and itching of dry skin with only 1 application per day
• SOOTHES itching*
• ELIMINATES scales*
• REDUCES discomforts and redness*
• EFFECTIVE against recurrence
*of dry skin
*patent pending
**due to dry skin
¹Clinical study on 57 subjects, 1 application/day, adults/teenagers. Immediate results.
²Clinical study on 57 subjects, 1 application / day, adults / teenagers. Results after 2 weeks of use, and proven anti-recurrence after 8 weeks
Using twice a week for maintenance helps to sustainably prevent the reappearance of scales and dry skin discomfort. Effectiveness demonstrated over 8 weeks.
In the intensive treatment phase, apply once a day for 2 weeks. To prevent recurrence, apply twice a week in the maintenance phase.
Avoid contact with eyes
Key ingredient known for its soothing properties
Ciclopirox Olamine combined with Piroctone Olamine works as a synergy of patented* key ingredients with fast-acting cleansing and soothing properties. *Patent pending
From the 1st application:
-74%² fewer scales**
-36%² less redness**
97%² satisfaction
Sustainable action²
**due to dry skin
¹Clinical study on 57 subjects, 1 application/day, adults/teenagers. Immediate results.
²Clinical study on 57 subjects, 1 application / day, adults / teenagers. Results after 2 weeks of use, and proven anti-recurrence after 8 weeks
